The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Politics

FDA phasing out some animal testing in ‘win-win’ for ethics and public health: commissioner

by admin April 11, 2025
April 11, 2025
FDA phasing out some animal testing in ‘win-win’ for ethics and public health: commissioner

— The Food and Drug Administration is phasing out an animal testing requirement for antibody therapies and other drugs in favor of testing on materials that mimic human organs, the FDA announced on Thursday. 

‘For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,’ FDA Commissioner Martin A. Makary, said in comment provided to Fox News Digital. 

 ‘By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices. It is a win-win for public health and ethics.’ 

The phase-out focuses on ending animal testing in regard to researching monoclonal antibody therapies, which are lab-made proteins meant to stimulate the immune system to fight diseases such as cancer, as well as other drugs, according to the press release. 

Instead, the FDA will encourage testing on ‘organoids,’ which are artificially grown masses of cells, according to the FDA’s press release obtained by Fox Digital. 

‘The FDA will promote the use of lab-grown human ‘organoids’ and organ-on-a-chip systems that mimic human organs – such as liver, heart, and immune organs – to test drug safety. These experiments can reveal toxic effects that could easily go undetected in animals, providing a more direct window into human responses,’ the press release says. 

The FDA will also encourage the use of AI while testing drugs, including building computer modeling that can predict a drug’s behavior, Fox Digital learned. 

The phase-out will include updating its guidelines to recognize research conducted on organoids and through AI.

‘Companies that submit strong safety data from non-animal tests may receive streamlined review, as the need for certain animal studies is eliminated, which would incentivize investment in modernized testing platforms,’ the FDA explained in its press release. 

The FDA is slated to also work with fellow federal agencies, such as the National Institutes of Health, the National Toxicology Program and the Department of Veterans Affairs, to ‘accelerate the validation’ of the new testing standards and will hold a public workshop later this year to further discuss the matter. 

‘For patients, it means a more efficient pipeline for novel treatments. It also means an added margin of safety, since human-based test systems may better predict real-world outcomes. For animal welfare, it represents a major step toward ending the use of laboratory animals in drug testing. Thousands of animals, including dogs and primates, could eventually be spared each year as these new methods take root,’ Makary said. 

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Mexican drug lord convicted in killing of DEA agent Enrique ‘Kiki’ Camarena is freed
next post
Is the Stock Market Getting Ready to Bounce? Key Market Breadth Signal Explained

Related Posts

Biden White House close to finalizing menthol cigarette...

April 4, 2024

Brennan directed publication of ‘implausible’ reports claiming Putin...

July 23, 2025

Israeli tanks roll into central Rafah for first...

May 29, 2024

Putin says Russia is open to economic cooperation...

February 25, 2025

Federal judge appointed by Trump quits group over...

March 12, 2025

Biden’s strange use of teleprompter in donor’s home...

July 9, 2025

Israel strikes site in Iran in retaliation for...

April 19, 2024

Iran ‘one to two weeks away’ from weapons-grade...

July 21, 2024

Germany poised to get new conservative chancellor Friedrich...

April 30, 2025

SEN BERNIE SANDERS: Two Americas, the people vs....

December 27, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Orange juice importer says Brazil tariffs will squeeze American consumers

      July 23, 2025
    • The Real Drivers of This Market: AI, Semis & Robotics

      July 23, 2025
    • Tech Taps the Brakes, Homebuilders Hit the Gas: See the Rotation on StockCharts Today

      July 23, 2025
    • GOP lawmakers advocate for US condemnation of persecution against Christians in Muslim-majority nations

      July 23, 2025
    • ‘Not going away’: Inside the Epstein drama that’s thrown House GOP into chaos

      July 23, 2025
    • Obama denies Trump’s ‘bizarre allegations’ that he was Russiagate ‘ringleader’ in rare statement

      July 23, 2025

    Categories

    • Business (1,300)
    • Politics (4,060)
    • Stocks (1,538)
    • Uncategorized (45)
    • World News (1,293)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved